Aptalis/Allerga Patent-Cliff Exposure & CMS Drug Spending Portfolio

Aptalis/Allerga (US): 4 reconciled FDA prescription therapies, $4.2M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies4
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$4.2M
2024 Medicare Part D Spend$2.2M
2024 Medicaid Spend$2.0M
California HCAI SB 17 Filings0 statutory filings in 2023 to 2026 panel